Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
- Details
- Category: Sanofi
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases.
Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
- Details
- Category: Novartis
Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible. The recruitment challenge facing our HCQ trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19.
Bayer supports "The Challenge Initiative" of Johns Hopkins Bloomberg School of Public Health with 10 million USD
- Details
- Category: Bayer
Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public Health, the initiative provides women and girls living in urban poverty in cities in Africa and Asia with family planning and reproductive health solutions.
Sanofi invests to make France its world class center of excellence in vaccine research and production
- Details
- Category: Sanofi
Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks. Aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines.
AstraZeneca to supply Europe with up to 400 million doses of Oxford University's vaccine at no profit
- Details
- Category: AstraZeneca
AstraZeneca has reached an agreement with Europe's Inclusive Vaccines Alliance (IVA), spearheaded by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of Oxford's COVID-19 vaccine, with deliveries starting by the end of 2020.
Gilead announces results from Phase 3 Trial of remdesivir in patients with moderate COVID-19
- Details
- Category: Gilead
Gilead Sciences, Inc. (Nasdaq: GILD) announced topline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone.
Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate; Phase 1/2a clinical trial to begin in second half of July
- Details
- Category: Johnson & Johnson
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the initiation of the Phase 1/2a first-in-human clinical trial of its investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant.
More Pharma News ...
- New consortium EUbOPEN will provide tools to unlock disease biology
- AstraZeneca takes next steps towards broad and equitable access to Oxford University's COVID-19 vaccine
- Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients
- Bayer to support Harvard Research Study to evaluate trust in science, including in COVID-19 pandemic
- Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia
- Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration
- AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine